^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
984P - Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
Published date:
09/05/2022
Excerpt:
In phase 2 of ARROW, 233 pts with RET fusion+ NSCLC (KIF5B n=164, CCDC6 n=41, Other n=28) received 400mg/day pralsetinib until progression, intolerance or withdrawal….Median duration of response (DOR) and progression-free survival (PFS) were higher with CCDC6 vs KIF5B RET fusions irrespective of prior treatment.
Trial ID:
